OTHER NEWS - Jan. 17, 1994

Eli Lilly & Co. Cutting AIDS Research: The giant pharmaceutical company has halted in-house research on HIV treatments as part of the pharmaceutical company’s continuing restructuring plans, officials said. The company’s AIDS and HIV research was limited, with just one potential drug in the first phase of human tests. That study won’t be abandoned, but Lilly will search for a partner to continue work. “There are other studies that are in the process of being . . . closed down in order for us to focus those resources in areas where we feel we have a competitive advantage,” said Carlos Lopez, executive director of infectious diseases research for Lilly. The move comes as the Indianapolis-based company tries to shrink its operations and staff to save money.